Avastin® (bevacizumab) Proposed Mechanism of Action
Genentech continues to study the mechanism of action of Avastin and role of VEGF and anti-VEGF therapy at various stages of tumor development. The mechanism of action of Avastin has been elucidated in preclinical studies.
1. Tumors release the VEGF protein causing nearby blood vessels to sprout new vessels — a process called angiogenesis. These blood vessels feed the growth of the tumor. They also provide a "highway" for tumor cells to spread to other parts of the body.1
2. Avastin is a therapeutic antibody that specifically binds to the VEGF protein — a potent source of angiogenesis.1
3. Avastin may block the tumor's ability to communicate with nearby blood vessels and may prevent the tumor from connecting to the blood supply.1
4. Studies have shown that targeting the VEGF protein with Avastin may interfere with a tumor's ability to grow.1
Avastin, in combination with intravenous 5-fluorouracil based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum. Avastin is not indicated for adjuvant treatment of colon cancer.
Avastin, in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.
Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.